Clinical Trials · NCT07668388
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 300
- Start date
- Jun 2026
- Locations
- 70 sites, 9 countries
- Primary endpoint
- UBT251: Change in glycated haemoglobin (HbA1c)